RDRishob Dasgupta

Rishob Dasgupta

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rishob Dasgupta has a total of 4 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Hidradenitis Suppurativa Is Associated with an Increased Risk of Adverse Cardiac Events and All-Cause Mortality

    by Thomas Z. Rohan, Ramsay Hafer, Teresa Duong, Rishob Dasgupta, Sherry Yang

    Background: Hidradenitis suppurativa (HS) has been previously associated with greater rates of major adverse cardiac events (MACEs) compared to the general population. This study aims to better elucidate the association between HS, MACEs, and other cardiovascular diseases. Methods: We utilized TriNetX, a global database of electronic health records, to conduct a retrospective cohort study. HS patients were matched on demographic and cardiovascular disease risk factors to both healthy and psoriasis groups as controls. Results: After adjusting for cardiovascular disease risk factors, HS patients had a relative risk (RR) (95% CI) of 2.06 (1.83–2.32) for myocardial infarction, 1.62 (1.44–1.82) for ischemic stroke, 2.21 (2.04–2.40) for heart failure, 1.95 (1.84–2.07) for MACEs, and 2.57 (2.34–2.83) for all-cause mortality compared to healthy controls. When comparing HS patients to matched psoriasis controls, HS patients had an RR of 1.31 (1.17–1.47) for myocardial infarction, 1.04 (0.93–1.16) for ischemic stroke, 1.24 (1.15–1.34) for heart failure, 1.16 (1.09–1.22) for MACEs, and 1.38 (1.27–1.5) for all-cause mortality. Herein, we demonstrate that patients with HS have increased rates of all cardiovascular diseases investigated when compared to healthy and psoriasis controls, even after adjusting for cardiovascular disease risk factors. Conclusions: These findings highlight the potential benefit in screening for and managing modifiable cardiovascular risk factors in HS patients.